FrontAce Medical completes Pre-A+ funding round to advance breakthroughs in precision treatment of peripheral lower extremity arterial disease

Recently, FrontAce Medical announced the successful completion of its Pre-A+ round of financing. This round was jointly invested by Anji Liangshan State Control Group and Zhejiang Anji State Control Construction Development Group.

Since its establishment in September 2022, FrontAce Medical has demonstrated strong resilience and consistent growth despite the challenging capital market environment, achieving three consecutive rounds of financing within three years. This success is attributed to its solid foundational technologies and clear clinical value. The newly raised funds will be primarily allocated to the research and development of new peripheral interventional devices and subsequent production line deployment. Additionally, the capital will accelerate the clinical registration process of its core product—the Sperstent® Peripheral Spot Stent System.

With the aging population in China, lower extremity peripheral artery disease (PAD) has become one of the fastest-growing chronic conditions. However, peripheral blood vessels, particularly the femoropopliteal segment, have long been regarded as a "high-risk zone" for stent therapy due to their exposure to multi-axial stresses such as stretching, compression, bending, and torsion during walking. After implantation of traditional long-segment metal stents, the primary patency rate at 12 months is less than 70%. Moreover, the permanent presence of the metal scaffold significantly limits subsequent treatment options.

As a result, the "Leave Nothing Behind" approach has emerged as a dominant trend in global peripheral vascular therapy. The focus of innovation in the industry has centered on addressing the dual challenge of effectively managing vascular dissections and residual stenosis while minimizing the retention of foreign materials.

As an innovative company in the peripheral vascular implant/interventional medical device field, driven primarily by technological innovation, FrontAce Medical has accurately identified this critical clinical challenge. Upholding the philosophy of "empowering clinical practice through technology and advancing healthcare via material innovation," the company has introduced the Sperstent® Peripheral Spot Stent System, which is built upon its proprietary intellectual property.

Sperstent® Peripheral Spot Stent System

Sperstent® represents a departure from the traditional "full-coverage" paving-style implantation by adopting a "spot" implantation technique. Physicians can provide precise support exclusively at the site of vascular lesions or dissections, significantly reducing the proportion of metal implants within the vessel. This approach not only preserves the natural physiological mobility of the blood vessel but also retains a valuable pathway for potential secondary interventional treatments that the patient may require in the future. Additionally, the system is equipped with a proprietary permanent functional coating, which further inhibits intimal hyperplasia and thrombosis, markedly enhancing long-term therapeutic outcomes.

Clinical data indicate that spot stents can increase the 12-month post-operative patency rate to over 95%, far surpassing the average rate of less than 70% associated with traditional long-segment stents. In key evaluation metrics, the Sperstent® spot stent demonstrates superior performance compared to both traditional long-segment stents and comparable overseas products. While realizing the concept of precision therapy, it also meets clinical needs in terms of both efficacy and safety.